Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
Astellas Pharma saw its sales grow over 6% in the first quarter of FY2021, but its profits tumbled due to impairment losses incurred from the termination of development projects, including its peanut allergy vaccine ASP0892. In April-June, the Japanese company…
To read the full story
Related Article
- Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls
October 31, 2025
- Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
- Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
- Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
April 28, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
- Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
November 2, 2022
- Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
- Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
- Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
February 3, 2022
- Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
November 1, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
February 1, 2021
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
August 5, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
BUSINESS
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
- Linepharma to Rebrand as Nordic Pharma Japan from 2026
December 11, 2025
- Espha/Bayer Unit Add Pediatric Indication to Xarelto AG
December 11, 2025
- Enhertu’s PIII Ovarian Cancer Trial Kicks Off for 1st-Line Maintenance Therapy
December 11, 2025
- Pfizer Files Hympavzi for Hemophilia with Inhibitors
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…